Attensi and SAP SuccessFactors Enter into a Strategic Partnership to Revolutionize Learning and Development
9.12.2021 10:00:00 EET | Business Wire | Press release
SAP SuccessFactors is the leading human capital management (HCM) solution, helping customers stay ahead of the competition to attract, develop and retain the best employees and ensuring a holistic employee journey throughout the employee lifecycle. Attensi delivers groundbreaking gamification and simulation-based training. Through this collaboration, the partners will offer an innovative learning experience using, among other approaches, gaming technology and competitive elements. The collaboration means that the two platforms work together to ensure a unified user experience and natural data flow, with the allocation and follow-up of learning as well as competence and development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208006137/en/
Attensi and SAP SuccessFactors enter into a strategic partnership to revolutionize learning and development. (Graphic: Business Wire)
“We are currently in an era of change and rapid technological development where learning and competence development are becoming increasingly more important to businesses. It is incredibly rewarding to be able to embrace successful HR tech "scale-ups" such as Attensi, so that we can offer innovative technology like this as part of our open ecosystem to the benefit of our rapidly growing customer community."
– Jens Conradi, Sales Director, SAP SuccessFactors
The solutions that Attensi offers combines advanced 3D simulation with deep insight into human behavior and psychology. Employees encounter virtual scenarios that are individually adapted to the individual business and bring to life actual experiences from the organization's reality. As employees evolve, they get educational, personalized feedback, and scores on their results. In addition, Attensi allows you to engage employees with automated campaigns and communication. As a manager, you can easily follow your team in real time, provide feedback to your employees, and measure the impact of the learning.
"The collaboration with SAP SuccessFactors is of strategic importance to Attensi. We can now offer customers who use SuccessFactors a seamless learning experience where the best elements of SuccessFactors play together with Attensi's solutions and platform. This enables even better and faster competence development and behavioral training for all the millions of employees in the companies that use SuccessFactors."
– Trond Aas, CEO, Attensi
"This is a major milestone in the development of the Attensi Technology Platform! Having achieved all qualifications required by SAP to enter a partnership recognizes Attensi as a top player in the field. We are extremely excited to provide our users access to world-leading learning technology delivered seamlessly in SAP SuccessFactor's global platform."
– Anne Lise Waal, CTO & COO, Attensi
About Attensi
Attensi delivers next generation simulation-based learning technology based on game mechanics and behavioral psychology that impacts KPIs and drives change in large organizations. Attensi is headquartered in Oslo, Norway, with offices in UK, USA and Germany and has delivered over 500 simulation solutions in over 20 languages to a global user base.
About SAP SuccessFactors
SAP's solutions help more than 400,000 customers around the world work better together using business insights more efficiently. Originally known for ERP software, SAP has evolved to become the market leader in business applications and related services for data, analytics, and intelligent technologies.
SAP SuccessFactors is a cloud-based, holistic HR solution that supports the entire employee journey including recruitment, onboarding, talent development, payroll, and HR analytics. SAP SuccessFactors provides personalized user experiences that facilitate competence development and more engaged and productive employees. SAP SuccessFactors has 200 million users in over 7,000 businesses worldwide, of which over 40 Norway. The solution is located in 101 countries and supports 43 languages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006137/en/
Contact information
Allison Knight for Attensi
attensi@10fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom